A Blue Bell biotech company born out of Temple University is entering a new phase, writes John George for the Philadelphia Business Journal.
ThirdLaw Molecular has fresh leadership, a rebrand, and multimillion-dollar backing. The company is now Ladder Bio, a nod to the distinctive ladder-like structure of its patented Spiroligomer molecules. The new class of compounds blends the best traits of small-molecule drugs and biologic medicines.
The rebranded company named Eric Heil as its new CEO following a $5.5 million seed round led by Medical Excellence Capital, which invested $3 million. Heil previously co-founded Horsham-based RightCare Solutions. Heil succeeds founder Dr. Christian Schafmeister, who remains president and will focus on scientific development.
Ladder Bio’s breakthrough molecules, invented by Schafmeister, can target proteins with high precision while offering advantages in cost, storage, and oral delivery compared to traditional biologics. The firm is developing drug candidates in inflammation, autoimmune disorders, and oncology, while also pursuing partnerships with major pharmaceutical companies.
The company has additionally received $16 million in U.S. Department of Defense grants to explore applications of its technology against viral and biological threats — positioning Blue Bell’s Ladder Bio as a growing player in Montgomery County’s expanding life sciences corridor.
To learn more about the latest from Blue Bell’s Ladder Bio, visit the Philadelphia Business Journal.
